Provident Financial Services, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anthony J. Labozzetta
- Full Time Employees
- 1,842
- Sector
- Financial Services
- Industry
- Banks - Regional
- Address
- 239 Washington Street Jersey City NJ United States of America 07302
- IPO Date
- Jan 16, 2003
- CIK
- 0001178970
- Website
- provident.bank
- Similar Companies
- Business
- Provident Financial Services, Inc. (NYSE:PFS) operates as the holding company for Provident Bank, a community-oriented financial institution that provides a comprehensive array of banking products and services to individuals, families, and businesses throughout northern and central New Jersey, eastern Pennsylvania, Bucks, Lehigh, and Northampton counties in Pennsylvania, and Orange, Queens, and Nassau counties in New York. Established in 1839 and headquartered in Iselin, New Jersey, the Bank offers deposit products including savings accounts, checking accounts, interest-bearing checking accounts, money market deposit accounts, certificates of deposit, and IRA products; loan products encompassing commercial real estate loans secured by multi-family apartment buildings, retail and industrial properties, and office buildings, commercial business loans, fixed-rate and adjustable-rate residential mortgage loans collateralized by one- to four-family properties, commercial construction loans, home equity loans and lines of credit, personal loans, unsecured lines of credit, auto loans, and recreational vehicle loans; wealth management, trust, and fiduciary services through its wholly owned subsidiary Beacon Trust Company; and insurance services through its wholly owned subsidiary Provident Protection Plus, Inc., including property and casualty insurance, employee benefits, and risk management solutions. The company maintains strong positions in commercial real estate lending, residential mortgage origination, asset-based lending, equipment lease financing, and treasury management services, with additional offerings in online and mobile banking, cash management, and small business administration loans. In May 2024, Provident Financial Services completed its merger with Lakeland Bancorp, Inc., creating a super community banking franchise with approximately $24.5 billion in assets, $18.8 billion in loans, $18.6 billion in deposits, and 140 branches across its operating footprint; the transaction enhanced scale, diversified revenue streams with added capabilities in asset-based lending, equipment financing, and mortgage warehouse lending, and resulted in board and executive leadership expansions including the appointment of Thomas J. Shara as Executive Vice Chairman. Prior to the merger close, the company successfully completed a $225 million public offering of 9.00% fixed-to-floating rate subordinated notes due 2034 in May 2024 to support regulatory requirements and general corporate purposes including debt repayment.
Company News
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
/C O R R E C T I O N - AbbVie/
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant
Provident Financial Services (NYSE:PFS) & F.N.B. (NYSE:FNB) Financial Review
Provident Financial Services (NYSE:PFS) & Capital Bancorp (NASDAQ:CBNK) Financial Comparison
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
Provident Financial Services (NYSE:PFS) vs. Popular (NASDAQ:BPOP) Critical Comparison
Provident Financial Services, Inc. Schedules Third Quarter Earnings Conference Call
Provident Bank Survey: 7 in 10 Americans Are Rethinking Higher Education, and Nearly 1 in 3 Are Eyeing the Alternatives
Provident Bank Goes Live with MANTL Business and Retail Account Opening Across its 135-Branch Network
Koryx Copper Completes PFS Drill Program, Announces Further Positive Infill Drill Results at the Haib Copper Project in Southern Namibia
RPX Gold Expands Gold Mineralization Beyond the PEA Open Pit and Underground Mine in Support of the Planned PFS
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu